| Publication number |
CLPUB00694 |
|---|
| Authors |
Story M.M., Stringer B.W., Fonseca-Alves C.E., Straw R.C., Laufer-Amorim R., Palmieri C. |
|---|
| Title |
Establishment and characterisation of a new canine prostate cancer cell line (Kodiak2016). |
|---|
| Citation |
(In conference) 4th joint ESVP, ECVP and ESTP cutting edge pathology congress; pp.?-?; European Society of Toxicologic Pathology, European Society of Veterinary Pathology, European College of Veterinary Pathologists; Torino; Italy (2021) |
|---|
| Web pages |
https://www.researchgate.net/publication/357685645 |
|---|
| Abstract |
Cultured cancer cell lines are critical for canine prostate cancer
research and represent an invaluable resource for the field of comparative
oncology. Research on canine prostate cancer is often hampered by the
difficultly in acquiring sufficient tissue samples for laboratory studies
and affected dogs for clinical studies, due to the relatively low
prevalence of canine prostate cancer compared to human prostate cancer and
the reluctance of owners to pursue diagnostic tests and treatment due to
the disease's very poor prognosis. While cell lines do not replace tissue
samples or in vivo studies, they provide another option for studying
canine prostate cancer. In addition, they can be used to help determine
what future studies are likely to be the most valuable, so that in vivo
studies and studies on tissue samples can be focused on these areas.
Basal, luminal and intermediate prostatic epithelial cells can be
differentiated based on the expression of cytokeratin 5 (CK5), cytokeratin
14 (CK14), cytokeratins 8 and 18 (CK8/18) and tumour protein 63 (p63).
Uroplakin III (UPIII) is expressed by urothelial cells but not by
prostatic cells and so can assist in differentiating tumours of urothelial
origin from those of prostatic origin. Nine canine prostatic carcinoma
cell lines have been described but comparison of the expression of CK5,
CK14, CK8/18, p63 and UPIII between the cell lines and the original
tumours has not been reported for any of them. This means it is not known
if the cell lines recapitulate the expression of these characterisation
markers by the original tumours. Thus, we established a new canine
prostatic carcinoma cell line and then compared the expression of these
characterisation markers between the original tumour, the cell line and a
non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse
xenograft, using immunohistochemistry (IHC) and immunofluorescence (IF).
We also performed whole genome sequencing (WGS) on the cell line to look
for genomic alterations.
|
|---|
| Cell lines |
CVCL_B7DS; Kodiak2016 |
|---|
